Press Releases

HAVN LIFE SCIENCES Inc. PROVIDES BI-WEEKLY MCTO STATUS UPDATE

Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management …

HAVN LIFE SCIENCES Inc. PROVIDES BI-WEEKLY MCTO STATUS UPDATE Read More »

HAVN LIFE SCIENCES Inc. PROVIDES BI-WEEKLY MCTO STATUS UPDATE

Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management …

HAVN LIFE SCIENCES Inc. PROVIDES BI-WEEKLY MCTO STATUS UPDATE Read More »

HAVN ANNOUNCES ANTICIPATED LATE FILING OF FINANCIAL STATEMENTS AND APPLICATION FOR MANAGEMENT CEASE TRADE ORDER

Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, announces it anticipates that it will miss the deadline (the “Filing Deadline”) of August 28, 2023, to file the following (collectively, …

HAVN ANNOUNCES ANTICIPATED LATE FILING OF FINANCIAL STATEMENTS AND APPLICATION FOR MANAGEMENT CEASE TRADE ORDER Read More »

HAVN LIFE ANNOUNCES CHANGE OF AUDITOR

Vancouver, BC – July 24, 2023 – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that, effective as of July 4, 2023 (the “Effective Date”), it has appointed …

HAVN LIFE ANNOUNCES CHANGE OF AUDITOR Read More »

HAVN LIFE PROVIDES CORPORATE UPDATE

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) announces that the Ontario and British Columbia Securities Commissions have issued a “failure to file” cease trade order in respect of the Company’s securities under Multilateral Instrument 11-103 Failure-to-File Cease Trade Orders in Multiple Jurisdictions (the “CTO”). …

HAVN LIFE PROVIDES CORPORATE UPDATE Read More »

HAVN Life Announces Retail Listing With Loblaws Company Ltd.

The Company’s line of plant and mushroom-based natural health products will be available at LCL grocery banners across Canada Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased …

HAVN Life Announces Retail Listing With Loblaws Company Ltd. Read More »

HAVN LIFE ANNOUNCES BOARD AND MANAGEMENT CHANGES

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) announces the departure of Mr. Gary Leong and Mr. Gordon Clissold as directors on the Board of the Company, effective immediately. Mr. Clissold is also departing as CFO of the Company. With Mr. Clissold’s departure, Mr Tim …

HAVN LIFE ANNOUNCES BOARD AND MANAGEMENT CHANGES Read More »

HAVN LIFE ANNOUNCES DEPARTURE OF TIM LAIDLER AS DIRECTOR

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) announces the departure of Mr. Tim Laidler as a director on the Board of the Company, effective immediately. On behalf of the Board, Mr. Tim Moore, Chairman of the Board, stated, “Mr. Laidler has been instrumental in …

HAVN LIFE ANNOUNCES DEPARTURE OF TIM LAIDLER AS DIRECTOR Read More »

HAVN Life Announces the close of the first tranche of its previously announced Financing Commitment by Alpha Blue Ocean and Warrant Amendments and the Issuance of Shares for Debt

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that it has closed the initial tranche (the “First Tranche“) of its financing commitment (the “Financing“) by …

HAVN Life Announces the close of the first tranche of its previously announced Financing Commitment by Alpha Blue Ocean and Warrant Amendments and the Issuance of Shares for Debt Read More »